FASN and obesity due to melanocortin 4 receptor deficiency: Currently, the FDA has approved drugs targeting FASN for obesity treatment, which also display potential role in blocking lipid synthesis in tumors; however, the clinical application of these drugs is limited by the development of drug resistance.76